A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once-Daily Oral LY3502970 Compared With Placebo in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-1) - J2A-MC-GZGP

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2031230136

Enrollment

3000

Registered

2023-06-13

Start date

2023-07-18

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity Overweight Overweight or Obesity

Interventions

Drug: Orforglipron Administered orally. Other Name: LY3502970 Drug: Placebo Administered orally. Study Arms Experimental: Orforglipron Dose 1 Participant will receive orforglipron administered orally

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Have a BMI >_30.0 kilogram/square meter (kg/m2), >_27.0 kg/m2 and presence of at least 1 of the following weight-related comorbidities (treated or untreated) at screening: Hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease (for example, ischemic cardiovascular disease, New York Heart Association Functional Class I-III heart failure). Have a history of at least 1 self-reported unsuccessful dietary effort to lose body weight.

Exclusion criteria

Exclusion criteria: Have Type 1 diabetes, Type 2 diabetes, or any other types of diabetes, history of ketoacidosis, or hyperosmolar state/coma Have a self-reported change in body weight >5 kg (11 pounds) within 90 days prior to screening. Have family (first-degree relative) or personal history of medullary thyroid cancer (MTC) or multiple endocrine neoplasia (MEN)2 syndrome. Have had a history of chronic or acute pancreatitis.

Design outcomes

Primary

Measure	Time frame
Mean Percent Change from Baseline in Body Weight [ Time Frame: Baseline to Week 72 ]	—

Countries

Brazil, China, India, Japan, Korea, Republic of, Puerto Rico, Slovakia, Spain, Taiwan, United States

Contacts

Public ContactTrial Guide Call Center

Eli Lilly Japan K.K.

LTG_CallCenter@lists.lilly.com+81-120-023-812

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026